Gray TSV

Language: Spanish
References: 11
Page:
PDF size: 360.43 Kb.

ABSTRACT

Neuroendocrine tumors are a heterogeneous group of tumors that are formed in cells capable to produce hormones in the blood which act as a result of a signal from the nervous system. Such tumors may produce more hormones than usual which causes different symptoms. They can develop in any organ of the body although its presentation in the digestive tract, pancreas and is more frequent bronchopulmonary tract.
Approximately 65% belong to the digestive tract, 25% to the bronchial pulmonary tract and 10% are considered as others. There is a diversity of clinical characteristics, which is associated with a low incidence, it is estimated at 6.98 new cases per 100,000 habitants, this makes them difficult to diagnose since in many cases the symptoms are either specific or found by chance, but in more than half of the cases the diagnosis is late when the disease is already advanced, so interdisciplinary management is necessary.
It is estimated the approximately more than 12,000 people in the United States are diagnosed with neuroendocrine tumors each year, 175,000 people are living with this disease. In Spain, 3,220 new cases are diagnosed each year and 17,000 patients are affected.

REFERENCES

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. NCCN. [Guideline]. 2022 [consultado el 24 de mayo, 2022]. Disponible a partir de: http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf.

2. Physician Data Query (PDQ). Carcinoma of Unknown Primary: Treatment. National Cancer Institute. [Internet]. [Consultado el 25 de mayo, 2014]. Disponible a partir de: www.cancer.gov/cancertopics/pdq/treatment/unknownprimary/HealthProfessional

3. American Cancer Society. Cancer Facts and Figures. [Internet]. 2016 [Consultado en 2016]. Disponible a partir de: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2016.html

4. American Cancer Society. Cancer Facts and Figures. [Internet]. 2017 [Consultado en 2017]. Disponible a partir de: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html

5. National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Occult primary. Version 3. [Internet]. 2014 [Consulted Jun 25, 2014]. Disponible a partir de: www.nccn.org

6. Greco FA, Hainsworth JD. Cancer of unknown primary site. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa.Lippincott Williams & Wilkins; 2011.p. 2033-2051.

7. Varadachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer. 2004;100:1776-1785.

8. Jerusalem G, Rorive A, Ancion G, et al. Diagnostic and therapeutic management of carcinoma of unknown primary: radio-imaginginvestigations. Ann Oncol. 2006;17 Suppl 10:168-176.

9. Mintzer DM, Warhol M, Martin AM, et al. Cancer of unknown primary: changing approaches. A multidisciplinary case presentation from the Joan Karnell Cancer Center of Pennsylvania Hospital. Oncologist. 2004;9:330-338.

10. Seve P, Sawyer M, Hanson J, et al. The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site. Cancer. 2006;106.2058-2066.

11. Neuroendocrine Tumor Research Foundation and Dasari A, et al.: Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342.